Regeneron's Dupixent Receives Approval in Japan for Pediatric Asthma Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Globenewswire
- Clinical Trial Success: Dupixent demonstrated significant efficacy in the global Phase 3 trial, reducing severe exacerbations in children with moderate-to-severe asthma by 54% to 65% and improving lung function by 4.68% to 5.32%, providing a new biologic treatment option with substantial market potential.
- Market Expansion in Japan: The approval from Japan's Ministry of Health, Labour and Welfare for Dupixent in children aged 6 to 11 years marks an expansion of its application in the pediatric population, expected to drive sales growth and enhance market competitiveness.
- Global Recognition: Dupixent has been approved in 50 countries worldwide, showcasing its broad applicability in pediatric asthma treatment and further solidifying Regeneron's leadership position in the biopharmaceutical sector.
- Technological Innovation: Developed using Regeneron's VelocImmune technology, Dupixent is the first biologic to target type 2 inflammation, and its successful launch will propel the company's further research and market expansion in related disease areas.
REGN
$779.36+Infinity%1D
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for REGN is 742.00 USD with a low forecast of 627.00 USD and a high forecast of 870.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
16 Buy
5 Hold
1 Sell
Moderate Buy
Current: 767.960
Low
627.00
Averages
742.00
High
870.00
Current: 767.960
Low
627.00
Averages
742.00
High
870.00
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
